Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 102.64%.

  • Rhythm Pharmaceuticals' EBITDA Margin rose 293400.0% to 102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 106.81%, marking a year-over-year increase of 1291400.0%. This contributed to the annual value of 204.04% for FY2024, which is 340700.0% up from last year.
  • Rhythm Pharmaceuticals' EBITDA Margin amounted to 102.64% in Q3 2025, which was up 293400.0% from 93.39% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' EBITDA Margin's 5-year high stood at 93.39% during Q2 2025, with a 5-year trough of 98280.0% in Q1 2021.
  • In the last 5 years, Rhythm Pharmaceuticals' EBITDA Margin had a median value of 458.03% in 2023 and averaged 6730.04%.
  • In the last 5 years, Rhythm Pharmaceuticals' EBITDA Margin soared by 947625800bps in 2022 and then crashed by -806800bps in 2024.
  • Rhythm Pharmaceuticals' EBITDA Margin (Quarter) stood at 2806.22% in 2021, then skyrocketed by 83bps to 478.99% in 2022, then skyrocketed by 64bps to 170.28% in 2023, then skyrocketed by 42bps to 98.63% in 2024, then dropped by -4bps to 102.64% in 2025.
  • Its EBITDA Margin stands at 102.64% for Q3 2025, versus 93.39% for Q2 2025 and 143.73% for Q1 2025.